Geisinger To Implement FDA Guidance On Zika Virus

The Food and Drug Administration (FDA) is recommending that blood banks screen all blood donations in the U. S. for the Zika virus. Geisinger Blood Center is working closely with the FDA to implement Zika virus testing in compliance with the new guidance and in accordance with the FDA timeline requirement of November 18.

Geisinger Blood Center is not in an area that is immediately affected by Zika, and there is no impact to the blood currently on our shelves. Geisinger Blood Center anticipates minimal impact to our donors and collections, no disruption to the community’s blood supply, or any effect on product distribution to our hospital partners, as a result of this request.

“Geisinger Blood Center has been anticipating the new guidance and communicating with the FDA to stay on top of this rapidly changing situation,” says

Dr. Darrell J. Triulzi, M. D., Geisinger Blood Center/ITxM Medical Director. “We are already in the process of implementing the changes necessary to begin testing. Our patients’ safety is our number one priority.”

Geisinger Blood Center will continue to monitor the most current information and communicate any notable changes as they occur. Providing safe blood products to hospitals and ultimately, patients in need, is our primary goal.

Areas with active transmission of the Zika virus are listed on the CDC website at http://www.cdc.gov/.